The prevention gap in post-stroke care
Every year, thousands of people in the Netherlands survive a hemorrhagic stroke—a rupture in a blood vessel in the brain. About a third of these survivors will experience another stroke within five years. While prevention strategies for ischemic strokes are well-established, evidence for effective interventions after a brain bleed has been lacking. Researchers involved in the study, published in The New England Journal of Medicine, noted that this disparity left a notable gap in care.
The lack of evidence wasn’t due to a lack of interest. Some researchers, including those at Radboudumc in Nijmegen, had suggested that stricter blood pressure control could help, but no large-scale study had confirmed this until now. The international trial, which included hospitals from ten countries, provided the necessary data. Patients who took a daily combination pill containing three low-dose blood pressure medications saw their risk of a second stroke drop by a meaningful margin. Their blood pressure was, on average, lower than those who took a placebo. The pill also reduced the risk of severe cardiovascular events, a concern for many stroke survivors.
Why a three-drug pill works where others fail
The combination pill used in the study isn’t new, but its application in post-hemorrhagic stroke care represents a shift in approach.
- Telmisartan, which widens and relaxes blood vessels;
- Amlodipine, which eases tension in the vessel walls;
- Indapamide, a diuretic that helps the body shed excess fluid.
The advantage of this combination lies in its low doses. By using smaller amounts of each medication than typically prescribed individually, the pill minimizes side effects. This is particularly important for stroke survivors, many of whom face challenges in managing their health after a brain bleed. A single pill, taken once a day, also simplifies adherence, which has been a persistent issue in long-term stroke prevention.
Researchers emphasized that the study reinforced the importance of blood pressure control. While the mechanism was already understood, the trial demonstrated its practical benefits in reducing recurrence. However, the study also highlighted ongoing challenges. Many patients with high blood pressure do not experience symptoms, making it difficult to recognize and treat. Others encounter barriers to consistent care, such as cost, access, or the difficulty of managing a chronic condition after a life-altering event.
For more on this story, see Foundayo: The GLP-1 Pill Changing Diabetes & Weight Loss.
What this means for guidelines—and patients
Current post-stroke care guidelines do not always distinguish between ischemic and hemorrhagic strokes when setting blood pressure targets. The new findings suggest that this approach may need to be reconsidered. The reduction in recurrence risk observed in the study could offer a meaningful benefit for patients who previously had limited options.
However, the results do not immediately change existing protocols. While the study addresses a key evidence gap, practical challenges remain. The pill is not yet widely available in all countries, and long-term monitoring will be necessary to confirm that the benefits persist over time. Risks, such as excessively low blood pressure, will also need to be carefully managed.
The study shifts the focus of stroke prevention. For years, much of the research has centered on ischemic strokes, which are more common. Hemorrhagic strokes, though less frequent, are often more severe, and survivors face a higher risk of recurrence. This research highlights the need for tailored strategies that account for the distinct risks associated with different types of strokes.
For patients, the findings offer a new perspective on recovery. A brain bleed is a serious medical event with lasting consequences. Many survivors experience long-term effects, and the risk of another stroke can be a constant concern. A treatment that reduces this risk by a significant margin provides an opportunity for improved outcomes and greater stability in their lives.
The road ahead: adoption, access, and unanswered questions
The study’s results are promising, but they also introduce new questions. Will healthcare systems adopt this approach quickly, or will cost and logistical challenges delay its implementation? How will patients who struggle with medication adherence respond to a new regimen? What about those who cannot tolerate even low-dose blood pressure medications?
The trial followed patients for several years, making it one of the longest studies of its kind for hemorrhagic stroke prevention. However, questions remain about the long-term durability of the benefits. Will the advantages persist after a decade, or could they diminish over time? How does this approach compare to other emerging treatments, such as surgical techniques or lifestyle interventions?
For now, the key takeaway is clear: for survivors of a brain bleed, managing blood pressure is a proven strategy to reduce the risk of another stroke. The challenge lies in ensuring that this strategy is accessible, affordable, and sustainable for those who need it most.
This study does more than change how we approach hemorrhagic stroke prevention—it changes the conversation. For too long, these patients have been underrepresented in stroke research. Now, they are at the forefront of discussions about how to improve their care and quality of life.
NRC and ZorgKrant contributed reporting to this article.
